ADTX vs. APVO, SXTC, CMRA, HSTO, BLPH, ATHX, AMPE, OBSV, EVFM, and SPRC
Should you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Aptevo Therapeutics (APVO), China SXT Pharmaceuticals (SXTC), Comera Life Sciences (CMRA), Histogen (HSTO), Bellerophon Therapeutics (BLPH), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), ObsEva (OBSV), Evofem Biosciences (EVFM), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
Aptevo Therapeutics has a net margin of 0.00% compared to Aptevo Therapeutics' net margin of -5,016.31%. Aditxt's return on equity of -221.61% beat Aptevo Therapeutics' return on equity.
Aptevo Therapeutics received 194 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
In the previous week, Aptevo Therapeutics had 1 more articles in the media than Aditxt. MarketBeat recorded 5 mentions for Aptevo Therapeutics and 4 mentions for Aditxt. Aptevo Therapeutics' average media sentiment score of 1.35 beat Aditxt's score of 1.20 indicating that Aditxt is being referred to more favorably in the news media.
8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 1.2% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aptevo Therapeutics has higher revenue and earnings than Aditxt.
Aditxt has a consensus target price of $61.00, suggesting a potential upside of 2,846.86%. Given Aptevo Therapeutics' higher probable upside, analysts plainly believe Aditxt is more favorable than Aptevo Therapeutics.
Aptevo Therapeutics has a beta of 5.13, suggesting that its share price is 413% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Summary
Aptevo Therapeutics beats Aditxt on 9 of the 14 factors compared between the two stocks.
Get Aditxt News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
